Thermimage Executives Visit Finland for CE and R&D Exploration

August 30, 2007 (Salt Lake City, Utah) – Thermimage Inc is pursuing market approval for the Thermaflux Scanner in Europe and company executives recently travelled to Finland to begin discussions with various agencies about CE approval and R&D. In early August, Douglas Turnquist, President & CEO, and Mark Prior, Chief Marketing Officer, visited officials from the US Embassy, R&D agencies, university research departments, funding groups and experts in medical device approval in the European Union. “Our initial impressions are that Finland is an excellent launching point for our European market efforts,” according to Turnquist. “Part of our strategy is to work the FDA approval process in parallel with the approval in the EU.” “The Finnish business climate is highly conducive to successfully bringing the Thermaflux Scanner to market in Europe,” noted Prior, “and we are pursuing R&D partners in that country.”

Thermimage Inc was founded in February 2007 to commercialize a non-invasive, painless and less costly way to produce deep-tissue temperature measurements. The device will first be used to diagnose Vesicoureteral Reflux (VUR) in children, a dangerous condition that allows urine to backflow into the kidneys of young children. The current procedure is painful and requires the use of catheters and ionizing radiation, where this new technique will heat the contents of the bladder and then detect any increase in temperature in the kidneys signaling reflux.

image
image
image